Amplification of Type II Cadherins in Prostate Cancer
Annual rept. 30 Oct 2007-29 Oct 2008
TEXAS UNIV HEALTH SCIENCE CENTER AT SAN ANTONIO
Pagination or Media Count:
Genomic alterations of 18q have been observed in prostate cancer. This research focuses on analyzing the role of increased gene copy number at 18q22.1 in prostate cancer. We believe the key genes in this region are type II cadherins. We are studying the role of overexpression of cadherin 7 CDH7, on the tumorigenic and invasive potential of prostate cancer cells. The increased copy number of CDH7 is specific to prostate cancer and results in increased levels of cadherin-7 mRNA in prostate tumors. We created monoclonal antibodies against full-length bacterially-expressed protein and have tested these antibodies for their use in immunohistochemistry experiments with paraffin-embedded prostate tissue. We now have an adequate anti-CDH7 antibody with which we can survey a prostate tumor tissue microarray to determine the levels of CDH7 protein. We have performed knockdown experiments of the CDH7 mRNA in a prostate cancer cell line. We are in the process of evaluating these prostate cancer cells knocked-down for CDH7 expression for invasive and tumorigenic potential both in vitro and in vivo.
- Medicine and Medical Research